Workflow
Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates
EKSOEkso Bionics(EKSO) ZACKS·2024-10-28 22:26

Company Performance - Ekso Bionics reported a quarterly loss of 0.10pershare,whichwasworsethantheZacksConsensusEstimateofalossof0.10 per share, which was worse than the Zacks Consensus Estimate of a loss of 0.08, and an improvement from a loss of 0.24pershareayearago,indicatingasurpriseof−250.24 per share a year ago, indicating a surprise of -25% [1] - The company posted revenues of 4.13 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 31.21%, and down from 4.61millioninthesamequarterlastyear[2]−Overthelastfourquarters,EksoBionicshasnotsurpassedconsensusEPSestimatesandhastoppedrevenueestimatesonlyonce[2]StockPerformance−EksoBionicsshareshavedeclinedapproximately58.44.61 million in the same quarter last year [2] - Over the last four quarters, Ekso Bionics has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Performance - Ekso Bionics shares have declined approximately 58.4% since the beginning of the year, contrasting with the S&P 500's gain of 21.8% [3] - The current consensus EPS estimate for the upcoming quarter is -0.05 on revenues of 6.42million,andforthecurrentfiscalyear,itis−6.42 million, and for the current fiscal year, it is -0.42 on revenues of $21.13 million [7] Industry Outlook - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]